Е. B. Zhigzhitova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Е. B. Zhigzhitova has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Albina A. Zhilina
Chita State Medical Academy
1 shared publication - Anna A. Filippova
Chita State Medical Academy
1 shared publication - Elena A. Tomina
Chita State Medical Academy
1 shared publication - Natalia V. Lareva
Chita State Medical Academy
1 shared publication - Svetlana M. Tsvinger
Chita State Medical Academy
1 shared publication - Zinaida M. Zhigula
Chita State Medical Academy
1 shared publication
Latest Publications
- 19 May 2026
- Published by Chita State Medical Academy in Transbaikalian Medical Bulletin
- No. 1,p. 189-199
Idiopathic pulmonary fibrosis: integration of modern diagnostic and therapeutic algorithms
Idiopathic pulmonary fibrosis (IPF) is a severe disease with an unfavorable prognosis, requiring a comprehensive, multidisciplinary approach to diagnosis and treatment. Its clinical presentation is dominated by nonspecific symptoms, primarily progressive dyspnea and cough, which clinicians may attribute to similar conditions (COPD, CHF, and others), thereby delaying verification of the diagnosis. Early diagnosis and the timely initiation of targeted therapy are crucial for improving patient outcomes. Antifibrotic medications (pirfenidone and nintedanib) are essential in IPF treatment, slowing pulmonary function decline and improving survival, particularly when initiated early. They exhibit comparable safety and efficacy profiles.
- 19 May 2026
- Published by Chita State Medical Academy in Transbaikalian Medical Bulletin
- No. 1,p. 189-199
Idiopathic pulmonary fibrosis: integration of modern diagnostic and therapeutic algorithms
Idiopathic pulmonary fibrosis (IPF) is a severe disease with an unfavorable prognosis, requiring a comprehensive, multidisciplinary approach to diagnosis and treatment. Its clinical presentation is dominated by nonspecific symptoms, primarily progressive dyspnea and cough, which clinicians may attribute to similar conditions (COPD, CHF, and others), thereby delaying verification of the diagnosis. Early diagnosis and the timely initiation of targeted therapy are crucial for improving patient outcomes. Antifibrotic medications (pirfenidone and nintedanib) are essential in IPF treatment, slowing pulmonary function decline and improving survival, particularly when initiated early. They exhibit comparable safety and efficacy profiles.